|Videos|December 13, 2021
Expert Discusses Innovative Add-On Study Design for Ibrutinib as Treatment for Chronic Lymphocytic Leukemia
Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the study design could affect future studies.
Advertisement
In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.
She discussed the innovative nature of the study design and how this could affect future studies.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
White House Expands TrumpRx, Adding Over 600 Generic Medications
2
FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC
3
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
4
Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Tirzepatide
5